Roche's new breast cancer treatment Kadcyla has been rejected by NICE in draft guidance, with the cost effectiveness watchdog criticising the high price set by the company. NICE says Kadcyla costs ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

An updated long-term analysis of the Phase III KATHERINE trial confirms that adjuvant treatment with Kadcyla (trastuzumab emtansine) significantly improves overall survival and long-term invasive ...

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights increased data management, DE&I, and ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial.